Under the deal, GSK will provide its pandemic vaccine adjuvant technology to enhance the development of an effective vaccine against 2019-nCoV virus. Coronaviruses are a family of viruses
The post GSK partners with CEPI to develop vaccine for novel Coronavirus appeared first on Pharmaceutical Business review.
Original Article: GSK partners with CEPI to develop vaccine for novel Coronavirus